Stem cells and cystic fibrosis  by Conese, Massimo & Rejman, Joanna
www.elsevier.com/locate/jcfJournal of Cystic FibrosisStem cells and cystic fibrosis
Massimo Conese a,b,*, Joanna Rejman a
a Institute for the Experimental Treatment of Cystic Fibrosis, San Raffaele Scientific Institute, Milan, Italy
b Department of Biomedical Sciences, University of Foggia, Foggia, Italy
Received 6 December 2005; received in revised form 8 February 2006; accepted 13 February 2006
Available online 6 March 2006Abstract
Although cystic fibrosis at first sight appears to be one of the most obvious human diseases to treat with gene therapy, since it is caused by
a single-gene defect and the main affected organ is the lung which is relatively easily accessible, clinical results have thus far been
disappointingly limited. At least one cause for this lack of success is the failure to permanently correct the gene defect in addition to the rapid
turnover of lung epithelial cells. Alternative approaches therefore involve the search for and use of stem cell populations. This review
presents an overview of recent attempts to identify lung- or bone marrow-derived populations of stem cells or progenitor cells and to apply
such cells, heterologous or gene-corrected autologous, to colonize the airways while differentiating into functional respiratory columnar
epithelial cells. The most successful approaches thus far appear to be obtained with bone marrow-derived cells such as mesenchymal stem
cells, although the transdifferentiation rate thus far has been limited to below the 1% level. As an alternative the proven multipotent nature of
bronchioalveolar stem cells isolated from lung tissue may provide another promising approach for successful stem cell therapy.
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is to permanently correct the genetic defect in the target
cellular compartment. This could conceivably be achieved
by gene transfer into the ‘‘stem’’ cell compartment of the
respiratory epithelium. Although the identification of a
resident pulmonary multipotent stem cell still remains to be
accomplished, it is clear that local stem or precursor cells
contribute to the repopulation of the injured epithelium in
different anatomical regions of the airways [1].
While repair and regeneration are naturally achieved in
mitotic cellular compartments, like the skin, it has long been1569-1993/$ - see front matter D 2006 European Cystic Fibrosis Society. Publish
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achieve this in so-called post-mitotic tissues, such as brain
and heart. Recently however, this concept was challenged
by the observation that these two organs contain multipotent
adult stem cells [2,3]. The role of these resident stem cells in
cardiac and neuronal regeneration, either occurring sponta-
neously or as a result of damage (i.e. in the case of a
myocardial infarction) is currently being studied.
Stem cell homing and engraftment into different organs
and new tissue formation are the major goals of regenerative
medicine. Thus far this has been accomplished in the heart
and the nervous system applying various sources of fetal
and adult stem cells [4]. Interestingly, hematopoietic stem
cells (HSCs) show developmental plasticity typical for
embryonic stem cells. It has been demonstrated that HSCs5 (2006) 141 – 143ed by Elsevier B.V. All rights reserved.
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bone marrow-derived cells (BMDCs) or enriched HSCs in
liver, lung, gut and skin epithelia has been detected after
transplantation of BMDCs or enriched HSCs into irradiated
recipient animals [5].
There are several stem cell niches that play a crucial role
in the renewal of the epithelial layers in the rodent lung.
Reynolds et al. demonstrated that progenitors of bronchial
Clara cells are essential for maintaining bronchial, bronchi-
olar, and alveolar epithelia [6]. Hong et al. identified a
population of basal cells that differentiate into Clara cells in
the proximal airway epithelium [7]. Stem cells residing at
the bronchioalveolar duct junctions were first described by
Giangreco et al. [8]. The multipotent nature of these lung
stem cells, called bronchioalveolar stem cells (BASCs), was
also reported by Kim et al. who demonstrated that single
BASCs give rise to colonies containing Clara cells and
alveolar type I and II cells [9].
There are a number of reasons why CF should be an ideal
disease for the application of gene therapy. First of all, it is
caused by a single-gene defect. Secondly, the main
pathology is in the lung, an organ which is relatively easily
accessible for treatment. In addition it offers a therapeutic
window for treatment since CF patients demonstrate an
almost normal phenotype at birth. Finally, it has been
suggested that restoration of CFTR function to a level of
only 5–10% of normal will suffice to adequately reverse the
chloride transport dysfunction [10,11] and give complete
recovery of the intestinal disease in CF mice [12]. However,
despite these encouraging features, clinical trials of gene
therapy in CF patients have only resulted in inconsistent and
low levels of vector-specific CFTR expression and at best
minor functional changes towards normality [13].
An alternative approach to cure CF is stem cell therapy,
which would require heterologous or gene corrected
autologous stem cells to colonize the airways, proliferate
there and differentiate into columnar cells covering a
sufficient part of the airway epithelium. Recent data indicate
that bone marrow-derived stem cells are able to contribute to
non-hematopoietic tissues, including epithelial lineages.
Importantly, it has been reported that circulating bone
marrow-derived stem cells are preferentially home to the
damaged respiratory epithelium undergoing regeneration
[14,15]. These observations are now being implemented in
the development of experimental treatments of CF. In this
context, two important studies have been published recently.
Loi et al. [16] determined whether transplantation of adult
marrow cells containing the gene for wild type Cftr might
result in functional Cftr expression in lung epithelium. The
authors transplanted two populations of bone marrow-
derived cells (cultured stromal marrow cells and total bone
marrow cells) containing the wild type Cftr gene into
transgenic Cftr knockout (KO) mice. Administration of
plastic adherent stromal cells to naive non-irradiated mice
resulted in the engraftment of donor-derived airway
epithelial cells, although at very small numbers (approxi-mately 0.025%). In contrast, no donor-derived airway
epithelial cells were detected in irradiated mice treated with
total marrow cells. Cftr mRNA and protein could only be
detected in the lungs of Cftr KO recipients treated with
isolated adherent bone marrow stromal cells. However, the
total number of chimeric lung epithelial cells exhibiting Cftr
expression was small (0.01%) and unlikely to affect overall
Cftr-dependent chloride transport and other functions in
airway epithelium, as we have pointed out before.
Most recently, Bruscia et al. [17] demonstrated that the
transplantation of GFP+/BMDCs of CFTR+/+ mice into
irradiated CFTR-null mice resulted in a partial restoration of
CFTR activity of gastrointestinal and nasal epithelium
(Bruscia E., personal communication). Most of the
CFTR/ mice had functional CFTR channels in the
rectum and nose by 5 months. These results correlated with
the presence of CFTR-expressing donor derived (GFP+)
columnar epithelial cells in the small intestine (with a
frequency of <1%).
Very promising results have been obtained recently by
Wang et al. [18]. In their experimental set-up mesenchymal
stem cells (MSCs) obtained from bone marrow of healthy
volunteers were mixed with airway epithelial cells (AECs)
and grown in air– liquid interface cultures on semi-
permeable filters. Almost 10% of the MSCs were induced
in vitro to acquire an epithelial phenotype, as judged by the
expression of cytokeratin 18 and occludin. Moreover, MSCs
obtained from CF patients corrected ex vivo with a CFTR-
encoding retrovirus and mixed with CF AECs resulted in
partial resumption of CFTR-mediated chloride current.
The in vivo experiments have suggested that the capacity
of transdifferentiation of HSCs into respiratory epithelial
cells is limited, i.e. only few percentages of cells showed the
cytokeratin pattern of expression (up to 0.6%) [19]. This
may be not sufficient to obtain a therapeutic effect, as it was
suggested by the work of Loi et al. [16]. However, a partial
restoration of CFTR activity was obtained in organs
(rectum, nose) easily investigated by the potential difference
technique [17], even though the protocol employed in this
last study (total body irradiation prior to bone marrow
transplantation) might not be applicable to CF patients.
It is conceivable that the injury models used to date
[14,15,20] are not appropriate to elicit a damage localised in
the anatomical target region for CF gene therapy, i.e. the
bronchi/bronchioli, indicating a need to exploit alternative
injury models. In addition, more insight into the molecular
mechanisms governing recruitment and phenotypic conver-
sion of bone marrow-derived cells is needed in order to
carry this approach to clinical feasibility.
The results published by Wang et al. [18] and Loi et al.
[16] strongly suggest that the population of bone marrow
cells relevant for repopulating the lung epithelium may be
found in the plastic adherent stromal cell compartment. Yet,
mesenchymal stem cells are not without drawbacks, e.g.
they are limited in numbers and lack well-defined markers
required for their purification [5]. One approach to
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of stem cells capable of repopulating damaged respiratory
epithelium. Recently, it has been shown that embryonic
stem cells can differentiate into a phenotypically mature
respiratory epithelium [21].
Other stem cell candidates considered suitable for cell
therapy of CF are the BASCs mentioned earlier. Importantly,
the use of Sca-1- and CD34-positive surface staining,
together with exclusion of hematopoietic and endothelial
lineage, will allow the isolation of BASCs by means of
fluorescence activated cell sorting (FACS) [9]. In addition, it
has been demonstrated that cultured BASCs can proliferate,
are able to self-renew and are multipotent in clonal assays.Acknowledgements
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